| Trial ID | NCT06514495 |
| Status | Recruiting |
| Condition | Agoraphobia; Panic |
| Intervention | Therapy |
Agoraphobia affects millions yet many patients avoid exposure therapy, the gold standard treatment, due to its intensity. This trial investigates whether virtual reality exposure therapy could provide comparable benefits to traditional in-vivo exposure while examining biological mechanisms that could predict treatment success.
This is a clinical trial comparing in-vivo exposure therapy to Virtual Reality Exposure Therapy (VRET) for agoraphobia patients. The study examines treatment outcomes alongside interoceptive accuracy (body awareness) and endocannabinoid system function as potential biomarkers. Researchers are investigating how these biological systems influence therapy response and whether VR exposure can match the efficacy of traditional exposure methods. The trial is currently recruiting participants with agoraphobia and panic disorder.
“If this trial demonstrates that VR exposure therapy produces comparable outcomes to traditional exposure, it could dramatically expand access to effective treatment for agoraphobia patients who find in-person exposure too daunting. Understanding endocannabinoid involvement could also inform future cannabis-based adjunct therapies.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This trial item was assembled from normalized source metadata and pipeline scoring.
